Investment bank BTIG initiated coverage of Hyperfine, Inc. on April 29, 2026, issuing a Buy rating and a bullish outlook [1], [2].

The move signals institutional confidence in the company's ability to disrupt traditional medical imaging. By moving MRI capabilities from centralized radiology departments directly to the patient's bedside, Hyperfine aims to reduce diagnostic delays and improve patient access to critical brain imaging.

BTIG set a price target of $2 [1] for the company, which trades on the NASDAQ exchange under the ticker HYPR. This target aligns with the average one-year price target for the stock as of April 28, 2026 [2]. According to analyst forecasts, this represents a potential upside of 46.22% [2].

The firm identified the Swoop System as a primary driver for this growth [1]. The Swoop System enables point-of-care brain MRI at the bedside, allowing clinicians to perform scans without transporting patients to a dedicated imaging suite. This portability is a central component of the company's market strategy.

Hyperfine's technology addresses a significant gap in acute care, where rapid brain imaging is often required for stroke or trauma patients. The ability to conduct these scans in the intensive care unit, or emergency department, could fundamentally change the workflow of neurological care.

BTIG's initiation of coverage provides a new benchmark for the stock's valuation as the company continues to scale its bedside imaging solutions. The bullish outlook reflects an expectation that the Swoop System will see increased adoption across healthcare facilities [1].

“BTIG issued a Buy rating and a bullish outlook, setting a price target of $2 for Hyperfine, Inc.”

The initiation of coverage by a firm like BTIG provides institutional validation for the portable MRI market. If the Swoop System achieves widespread clinical adoption, it could shift the economics of medical imaging by reducing the reliance on expensive, stationary MRI infrastructure and decreasing the time between symptom onset and diagnosis for neurological emergencies.